JORVEZA (Dr Falk Pharma Australia Pty Ltd)
Product name
JORVEZA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
194 (255 working days)
Active ingredients
Budesonide
Registration type
EOI
Indication
Jorveza 0.2 mg/mL oral suspension is indicated for the treatment of EoE in paediatric patients aged 2 to 17 years.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.